Literature DB >> 21741819

Characterization of responses of 2d array seven29 detector and its combined use with octavius phantom for the patient-specific quality assurance in rapidarc treatment delivery.

S A Syamkumar1, Sriram Padmanabhan, Prabakar Sukumar, Vivekanandan Nagarajan.   

Abstract

A commercial 2D array seven29 detector has been characterized and its performance has been evaluated. 2D array ionization chamber equipped with 729 ionization chambers uniformly arranged in a 27 × 27 matrix with an active area of 27 × 27 cm² was used for the study. An octagon-shaped phantom (Octavius Phantom) with a central cavity is used to insert the 2D ion chamber array. All measurements were done with a linear accelerator. The detector dose linearity, reproducibility, output factors, dose rate, source to surface distance (SSD), and directional dependency has been studied. The performance of the 2D array, when measuring clinical dose maps, was also investigated. For pretreatment quality assurance, 10 different RapidArc plans conforming to the clinical standards were selected. The 2D array demonstrates an excellent short-term output reproducibility. The long-term reproducibility was found to be within ±1% over a period of 5 months. Output factor measurements for the central chamber of the array showed no considerable deviation from ion chamber measurements. We found that the 2D array exhibits directional dependency for static fields. Measurement of beam profiles and wedge-modulated fields with the 2D array matched very well with the ion chamber measurements in the water phantom. The study shows that 2D array seven29 is a reliable and accurate dosimeter and a useful tool for quality assurance. The combination of the 2D array with the Octavius phantom proved to be a fast and reliable method for pretreatment verification of rotational treatments. Copyright Â
© 2012 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21741819     DOI: 10.1016/j.meddos.2010.12.013

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  6 in total

1.  A critical evaluation of the PTW 2D-ARRAY seven29 and OCTAVIUS II phantom for IMRT and VMAT verification.

Authors:  Mohammad Hussein; Elizabeth J Adams; Thomas J Jordan; Catharine H Clark; Andrew Nisbet
Journal:  J Appl Clin Med Phys       Date:  2013-11-04       Impact factor: 2.102

2.  Assessment of Imprecise Small Photon Beam Modeling by Two Treatment Planning System Algorithms.

Authors:  Hadi Keivan; Daryoush Shahbazi-Gahrouei; Ahmad Shanei; Alireza Amouheidari
Journal:  J Med Signals Sens       Date:  2018 Jan-Mar

3.  Effectiveness of Multi-Criteria Optimization-based Trade-Off exploration in combination with RapidPlan for head & neck radiotherapy planning.

Authors:  Eliane Miguel-Chumacero; Garry Currie; Abigail Johnston; Suzanne Currie
Journal:  Radiat Oncol       Date:  2018-11-23       Impact factor: 3.481

4.  Critical appraisal of the accuracy of Acuros-XB and Anisotropic Analytical Algorithm compared to measurement and calculations with the compass system in the delivery of RapidArc clinical plans.

Authors:  Murugesan Kathirvel; Shanmuga Subramanian; Alessandro Clivio; Gandhi Arun; Antonella Fogliata; Giorgia Nicolini; Vellaiyan Subramani; Shanmugam Thirumalai Swamy; Eugenio Vanetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2013-06-11       Impact factor: 3.481

5.  Measurement comparison and Monte Carlo analysis for volumetric-modulated arc therapy (VMAT) delivery verification using the ArcCHECK dosimetry system.

Authors:  Mu-Han Lin; Sion Koren; Iavor Veltchev; Jinsheng Li; Lu Wang; Robert A Price; C-M Ma
Journal:  J Appl Clin Med Phys       Date:  2013-05-06       Impact factor: 2.102

6.  A Homogeneous Water-Equivalent Anthropomorphic Phantom for Dosimetric Verification of Radiotherapy Plans.

Authors:  Manikandan Arjunan; Sureka Chandra Sekaran; Biplab Sarkar; Sujatha Manikandan
Journal:  J Med Phys       Date:  2018 Apr-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.